Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals develops clinical-stage immunotherapy medicines built around rose bengal sodium, a synthetic small molecule in the halogenated xanthene family. News about PVCT centers on its PV-10 and PV-305 formulations, research publications, preclinical disease models, and clinical-program activity across oncology, dermatology, and ophthalmology.
Recurring updates also cover VisiRose, the company’s ocular-therapeutics subsidiary, and rose bengal photodynamic antimicrobial therapy for infectious keratitis and other eye infections. Additional company announcements address proof-of-concept work in wound healing, infectious disease, tissue repair, hematology, and vaccine-adjuvant research, along with annual-meeting and other public-company governance matters.
Provectus (OTCQB: PVCT) announced the acceptance of two abstracts for the ASCO 2021 Annual Meeting, showcasing the potential of PV-10, an investigational cancer immunotherapy. The first abstract details a Phase I clinical trial focused on intralesional PV-10 administration for metastatic neuroendocrine tumors, conducted at The Queen Elizabeth Hospital in Australia. The second abstract presents preclinical research on the oral administration of PV-10 for treating high-risk adult solid tumors. Both presentations highlight the ongoing research and potential applications of PV-10 in cancer therapy.
Provectus (OTCQB: PVCT) announced a published study on PV-10, showing a 46% complete response rate and 86% overall response rate in treating in-transit melanoma lesions in 48 patients. Conducted at the Melanoma Institute Australia, the study highlights a median age of 75.1 years for participants and significant overall survival rates of 77% and 56% at 12 and 24 months, respectively. This publication marks the fifth study of PV-10, emphasizing its potential as a low-toxicity treatment option for patients with limited alternatives.
Provectus (OTCQB: PVCT) announced that the USPTO has allowed its patent application 16/678,133, covering the use of intralesional PV-10 in combination with immune checkpoint inhibitors for adult solid tumor cancers. This includes melanoma, breast, liver, prostate, and lung cancers. The allowed patent is the fourth continuation of a foundational cancer treatment patent granted in 2015. Vice Chair Dominic Rodrigues highlighted that this new patent strengthens their oncology drug development program, focusing on the combination therapies that enhance immune response against solid tumors.
Provectus announced that the USPTO has allowed patent application 16/412,872, which pertains to the use of PV-10, an injectable formulation of rose bengal disodium, for treating relapsed and refractory pediatric solid tumor cancers. This patent represents the initial intellectual property from the company's collaboration with Dr. Aru Narendran at the University of Calgary. The patent supports both monotherapy and combined treatments with immune checkpoint blockade or radiotherapy. Provectus aims to further develop its intralesional oncology drug program to enhance cancer treatment options.
Provectus (OTCQB: PVCT) announced that H. Lee Moffitt Cancer Center will present non-clinical data on PV-10, an injectable cancer immunotherapy using rose bengal disodium (RBD), at the SITC 2020 Annual Meeting (Nov 9-14, 2020). The presentation will include research on the drug's efficacy, especially in combination with chemotherapy for pancreatic cancer. PV-10 aims to induce immunogenic cell death in tumors through lysosome disruption. This follows previous positive findings on RBD's immune responses in various cancers, with ongoing clinical studies for adult and pediatric solid tumor cancers.
Provectus (OTCQB: PVCT) has completed enrollment of 12 patients in its Phase 1 study of PV-10, an injectable cancer immunotherapy targeting neuroendocrine tumors (NET) that are resistant to standard treatments. The therapy utilizes rose bengal disodium (RBD) to induce cell death in tumors. The primary focus is on safety, with secondary endpoints assessing response rates and receptor expressions. The company plans to engage with Australia’s Therapeutic Goods Administration for an end-of-phase meeting in Q1 2021.